GLP1R and metabolic dysfunction-associated steatohepatitis: The approval of GLP-1R agonists for obesity and diabetes mellitus has resulted in higher demand and prescription for these indications, and a GLP-1R agonist is currently in a phase 3 clinical trial in metabolic dysfunction-associated steatohepatitis (MASH)1.